Datasheet Inhibitors / / Screening Libraries A DRUG SCREENING EXPERT

Product Name : Rocuronium bromide Catalog Number : T0156 CAS Number : 119302-91-9 Molecular Formula : C32H53BrN2O4 Molecular Weight : 609.68 Apprearence : Solid Melting Point : 162-164°C

Description: Rocuronium is a or non-depolarizing neuromuscular blocker. During or , it is used to facilitate endotracheal intubation and to provide skeletal muscle relaxation.

Storage: 2 years -80°C in solvent; 3 years -20°C powder;

DMSO 113 mg/mL (185.3 mM) Ethanol 113 mg/mL (185.3 mM) Solubility Water 112 mg/mL (183.7 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble )

Receptor (IC50) mAChR

In vitro Activity Rocuronium bromide (RB), an aminosteroid type neuromuscular blocking agent, acts by reducing or inhibiting the depolarising effect of on the terminal disc of the muscle cell. [1] Rocuronium interacts with human liver microsomal cytochromes P450 (CYP) by binding to the substrate site. Rocuronium has caused inhibition of both reactions by 20 and 15%, respectively. [2] In vivo Activity Rocuronium is an ideal muscle relaxant with a rapid onset, intermediate duration of action, nondepolarizing properties and lack of cardiovascular side effects. Rocuronium produces a dose-dependent duration of neuromuscular blockade in anesthetized horses. [3] Rocuronium bromide, is a relatively low potency, intermediate-acting agent with a rapid onset time of 98 seconds in dogs. [4] Rocuronium is an effective nondepolarizing muscle relaxant in the cat under the clinical conditions of this study. Rocuronium has a rapid onset, a short duration of action. [5] Rocuronium (0.6 mg/kg) results in a significant increase in heart rate one min after IV administration in the dog. Rocuronium (0.3 mg/kg and 0.6 mg/kg) produce a reliable neuromuscular block of 23–32 min duration, respectively. [6] Rocuronium bromide paralyzes the internal laryngeal muscles keeping the vocal cords in an intermediate position (paramedial) 60 seconds after being administered in cats. [7]

Reference 1. Zan U, et al. Cytotechnology,2011, 63(3), 239-245. 2. Anzenbacherova E, et al. J Pharmacol Sci,2015, 127(2), 190-195. 3. Auer U, et al. Vet Ophthalmol,2011, 14(4), 244-247. 4. Tachibana M, et al. Pharmacology,2003, 68(2), 96-104. 5. Auer U, et al. Vet Anaesth Analg,2006, 33(4), 224-228. 6. Auer U, et al. Vet J,2007, 173(2), 422-427. 7. Moreno-Sala A, et al. Vet Anaesth Analg,2013, 40(4), 351-358.

FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, please follow the storage recommendations on the product data

[email protected] | Tel: +1-781-999-4286 | www.targetmol.com Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT sheet.

[email protected] | Tel: +1-781-999-4286 | www.targetmol.com